---
title: Effect of Renal Denervation on Bood Pressure in Patients on Hemodialysis
nct_id: NCT06556407
overall_status: RECRUITING
phase: NA
sponsor: University of Erlangen-Nürnberg Medical School
study_type: INTERVENTIONAL
primary_condition: Treatment Resistant Hypertension
countries: Germany
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06556407.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06556407"
ct_last_update_post_date: 2025-09-26
last_seen_at: "2026-05-12T06:32:28.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Effect of Renal Denervation on Bood Pressure in Patients on Hemodialysis

**Official Title:** Effect of Renal Denervation on Blood Pressure in Patients With Treatment Resistant Hypertension, End-stage Chronic Kidney Disease and Hemodialysis

**NCT ID:** [NCT06556407](https://clinicaltrials.gov/study/NCT06556407)

## Key Facts

- **Status:** RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 12
- **Lead Sponsor:** University of Erlangen-Nürnberg Medical School
- **Conditions:** Treatment Resistant Hypertension, Chronic Hemodialysis
- **Start Date:** 2024-03-04
- **Completion Date:** 2026-12-01
- **CT.gov Last Update:** 2025-09-26

## Brief Summary

The RDN-HD Study is a prospective, single-center feasibility study. All patients included will undergo endovascular ultrasound-based RDN (no sham group, no blinding). The purpose of the RDN-HD Study is to demonstrate that ultrasound-based RDN is safe in patients with TRH and ESRD hemodialysis and reduces 24-h ambulatory BP.

## Detailed Description

Patients with end-stage renal disease (ESRD) and hemodialysis have a very high risk for cardiovascular events and a very high cardiovascular mortality. Uncontrolled treatment resistant hypertension (TRH) is an important factor driving this very high cardiovascular event risk. Clinical and experimental studies have clearly shown that sympathetic nerve activity is increased in patients with chronic kidney disease (CKD) and substantially aggravates the progression of CKD. In patients with ESRD and chronic hemodialysis bilateral nephrectomy reduced increased sympathetic nerve activity. Interestingly, kidney transplantation did not normalize peripheral sympathetic activity unless the native kidneys were removed. Thus, afferent sensory nerve signaling from the diseased kidneys to the central nervous system is an important pathophysiologic mechanism in CKD leading to sympathetic overactivity and hypertension. Clinical studies have demonstrated that invasive, catheter-based renal denervation (RDN) decreases the sympathetic nerve activity in the whole body and in particular in the kidneys

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 99 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Uncontrolled treatment resistant hypertension (despite intake of 3 different classes of antihypertensive medications) confirmed by 24-h ambulatory blood pressure according to current guidelines (ESH 2023) (office blood pressure ≥ 140/ and/ or ≥ 90 mmHg and ambulatory blood pressure ≥ 130/ and/or ≥ 80 mmHg
* end-stage renal disease on chronic hemodialysis
* Stable hemodialysis regime for at least 3 months based on the decision of the treating physician
* Patient is adhering to a stable drug regimen without changes for a minimum of 4 weeks.
* Individual is ≥ 18 years of age, male and female patients are included.

Exclusion Criteria:

* Episodes of sustained systolic and/or diastolic hypotension according to 24-h ambulatory blood pressure or dialysis protocols which in the eyes of the treating physician would interfere with a safe renal denervation treatment of the patient
* Known hemodynamically or anatomically significant renal artery abnormality or stenosis in either renal artery which in the eyes of the interventionalist would interfere with safe catheter placement
* Prior renal denervation procedure
* Anatomic or functional solitary kidney, kidney transplantation
* Severe atherosclerotic disease or artery calcification preventing the assessment of reliable BP measurements
* Endocrine hypertension other than obstructive sleep apnea
* Individual has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 3 months of the screening visit
* Acute episode of systemic and renal disease requiring uptitration of any immunosuppressive drug regimen within the last 3 months
* Subject is pregnant, nursing, or intends to become pregnant
* Enrollment in another interventional research protocol.
* Any condition that, at the discretion of the investigator, would preclude participation in the study (e.g. non-adherence)
```

## Arms

- **Treatment** (OTHER) — Intervention: Renal denervation

## Interventions

- **renal denervation** (DEVICE) — ultrasound based renal denervation

## Primary Outcomes

- **Safety endpoints and adverse effects** _(time frame: during 6 months post-procedure)_ — A major combined safety endpoint is the incidence of any major adverse events (MAE) through the 6 months FU
- **Change in 24-h ambulatory systolic blood pressure between baseline and 3 months post-procedure** _(time frame: baseline and 3 months post-procedure)_

## Secondary Outcomes

- **Change in 24-h ambulatory systolic blood pressure between baseline and 6 months post-procedure** _(time frame: between baseline and 6 months post-procedure.)_
- **Change in 24-h ambulatory diastolic blood pressure between baseline and 3, 6 months post-procedure** _(time frame: baseline and 3, 6 months post-procedure.)_
- **Change in office (attended) systolic and diastolic blood pressure between baseline and 3, 6 months post-procedure** _(time frame: between baseline and 3, 6 months post-procedure)_
- **Change in systolic and diastolic home blood pressure between baseline and 3, 6 months post-procedure.** _(time frame: between baseline and 3, 6 months post-procedure)_
- **Number of antihypertensive drugs, doses, classes at 3, 6 months post-procedure compared to baseline.** _(time frame: at 3, 6 months post-procedure compared to baseline.)_
- **Change in bio-impedance parameters between baseline and 3, 6 months post-procedure to assess the volume status.** _(time frame: between baseline and 3, 6 months post-procedure)_
- **Change in central systolic and diastolic blood pressure, central pulse pressure and pulse wave velocity between baseline and 3,6 months post procedure** _(time frame: between baseline and 3,6 months post procedure)_
- **Change in retinal arteriolar wall to lumen ratio between baseline and 3,6 months post procedure** _(time frame: between baseline and 3,6 months post procedure)_
- **Change in average daytime/night-time ambulatory systolic blood pressure between baseline and 3, 6 months post-procedure.** _(time frame: between baseline and 3, 6 months post-procedure.)_
- **Change in average daytime/night-time ambulatory diastolic blood pressure between baseline and 3, 6 months post-procedure** _(time frame: between baseline and 3, 6 months post-procedure)_
- **Change in office (attended) and ambulatory heart rate between baseline and 3, 6 months post-procedure** _(time frame: between baseline and 3, 6 months post-procedure)_
- **Changes in dipper/non-dipper patterns between baseline and 3, 6 months post-procedure** _(time frame: between baseline and 3, 6 months post-procedure)_
- **Change in retinal arterial remodeling between baseline and 3, 6 months post-procedure** _(time frame: between baseline and 3, 6 months post-procedure)_
- **Change in retinal capillary density between baseline and 3, 6 months post-procedure** _(time frame: between baseline and 3, 6 months post-procedure)_

## Locations (1)

- Friedrich Alexander University Erlangen Nuremberg, Department of Nephrology and Hypertension, Erlangen, Bavaria, Germany — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.friedrich alexander university erlangen nuremberg, department of nephrology and hypertension|erlangen|bavaria|germany` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06556407.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06556407*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*